NeueHealth (NYSE:NEUE) and Oncology Institute (NASDAQ:TOI) Head to Head Comparison

NeueHealth (NYSE:NEUE) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares NeueHealth and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeueHealth	-14.28%	-6.40%	-17.46%
Oncology Institute	-15.38%	-445.02%	-34.13%

Earnings & Valuation

This table compares NeueHealth and Oncology Institute”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeueHealth	$936.66 million	0.07	-$134.68 million	($22.00)	-0.31
Oncology Institute	$393.41 million	0.51	-$64.66 million	($0.70)	-3.20

Oncology Institute has lower revenue, but higher earnings than NeueHealth. Oncology Institute is trading at a lower price-to-earnings ratio than NeueHealth, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

NeueHealth has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NeueHealth and Oncology Institute, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeueHealth	0	1	0	0	2.00
Oncology Institute	0	0	1	0	3.00

NeueHealth presently has a consensus target price of $7.00, suggesting a potential upside of 2.56%. Oncology Institute has a consensus target price of $7.00, suggesting a potential upside of 212.50%. Given Oncology Institute’s stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than NeueHealth.

Institutional and Insider Ownership

63.9% of NeueHealth shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 63.3% of NeueHealth shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NeueHealth beats Oncology Institute on 8 of the 14 factors compared between the two stocks.

About NeueHealth

NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.